DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday

DBV Technologies (NASDAQ:DBVT) is expected to be issuing its Q4 2025 results before the market opens on Friday, April 10th. Analysts expect the company to announce earnings of ($0.1564) per share and revenue of $1.0890 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, April 2, 2026 at 7:00 AM ET.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share for the quarter. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%. The firm had revenue of $0.65 million for the quarter. On average, analysts expect DBV Technologies to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

DBV Technologies Trading Up 2.7%

DBV Technologies stock opened at $21.06 on Friday. The company has a 50-day moving average price of $21.49 and a 200 day moving average price of $17.53. DBV Technologies has a 12-month low of $6.00 and a 12-month high of $26.18. The stock has a market cap of $1.17 billion, a P/E ratio of -4.03 and a beta of -0.94.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada acquired a new stake in DBV Technologies in the 4th quarter valued at about $34,000. Truvestments Capital LLC grew its position in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of DBV Technologies during the fourth quarter worth approximately $115,000. Two Sigma Investments LP acquired a new stake in DBV Technologies in the third quarter valued at approximately $167,000. Finally, Citadel Advisors LLC acquired a new stake in DBV Technologies in the third quarter valued at approximately $220,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DBVT. Guggenheim restated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a report on Friday, March 27th. Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Citizens Jmp upped their price target on DBV Technologies from $45.00 to $47.00 and gave the company a “market outperform” rating in a research note on Friday, March 27th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, DBV Technologies presently has an average rating of “Moderate Buy” and an average price target of $38.65.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.